Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Filed, Not Forgotten: FTC Signals Antitrust Scrutiny Of Patent Application Acquisitions In ...

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

operational-macro

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at mondaq.com →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

The FTC has filed a brief arguing that acquiring exclusive rights to patent applications, even before patents are granted, can face antitrust scrutiny due to their ability to extend monopolies and block competition in biologic drug markets.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You now face antitrust risk when acquiring patent applications to block competition in biologics. This is a clear warning that patent deals once seen as safe can trigger enforcement.

◆ Coverage

1 source · 7 Sep 2026

◆ Related on Wire

◆ Topics

Healthftcpatent-applicationsantitrustbiologicsdrug-pricing